Completed PHASE2 INTERVENTIONAL 2-arm NCT00487721

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

A Pilot Biomarker Study of Oral Silybin-Phytosome Followed by Prostatectomy in Patients With Localized Prostate Cancer

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Updated 9 times since 2017 Last updated: Mar 3, 2014 Started: Aug 31, 2006 Primary completion: Sep 30, 2007 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00487721, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Sir Mortimer B. Davis - Jewish General Hospital, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sir Mortimer B. Davis - Jewish General Hospital
University of Colorado, Denver

Data source: University of Colorado, Denver

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aurora, United States